SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) was one of the stocks on Jim Cramer’s radar on Mad Money as he explained that many investors might be missing out on the market’s biggest winners. Responding to a caller’s question about the company, Cramer stated:
Oh, this life science company that is, look, okay, so this is a good example. This stock’s up a great deal, alright? And you know, it’s losing a little money. It’s a great spec, and even though it’s up, I used to say, you know, I can’t touch it. I used to say that. I can’t do that right now, I can’t. I’m going to say two thumbs up or whatever to SLS. It. It’s that kind of market.
Photo by Yiorgos Ntrahas on Unsplash
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) is a clinical-stage company focused on creating new treatments for cancer, specifically targeting the disease with its main product candidates, galinpepimut-S and SLS009. To advance these treatments forward, the company partners with major names like Merck, GenFleet Therapeutics, and Memorial Sloan Kettering Cancer Center for clinical trials and development.
While we acknowledge the potential of SLS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Disclosure: None. Follow Insider Monkey on Google News.
